Literature DB >> 12029549

Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.

Susanne M Eschmann1, Gerald Reischl, Kilian Bilger, Juergen Kupferschläger, Marcel H Thelen, Bernhard M Dohmen, Hariolf Besenfelder, Roland Bares.   

Abstract

The aim of this study was to evaluate the use of 124I positron emission tomography (PET) to determine the dosimetry of radioiodine therapy in hyperthyroidism and thyroid cancer. Phantom studies to assess the accuracy of PET were performed using an EEC phantom with spheres of different diameters filled with 3-30 MBq of 124I. Patient dosimetry was derived from PET data obtained 1-13 days after simultaneous oral administration of a therapeutic dose of 131I and a diagnostic dose of 124I. The obtained data were compared with findings from intratherapeutic probe measurements and clinical outcome. The phantom studies confirmed that 124I can be quantitated by PET (imprecision < or =10%), and volumetry is feasible for nodules <13 mm (imprecision < or =20%). Any influence of contamination with 123I or the simultaneous administration of 131I on the accuracy of the PET quantification and the probe measurements was ruled out by phantom measurements with solutions of 131I, 124I and 123I in various ratios. In autonomous nodular goitres, radioiodine uptake measured by PET varied from 25.4% to 64.3% and was not significantly different from that obtained by a scintillation probe (24.1%-73.1%, correlation coefficient r=0.91). Comparison of uptake and effective half-life in normal tissue versus autonomous nodules revealed significant differences in uptake but not in effective half-life [uptake 2.0-8.3 kBq/(ml x MBq) in normal tissue vs 12.6-29.3 kBq/(ml x MBq) in nodules; half-life 97.8-156.7 h in normal tissue vs 73.3-192.3 h in nodules]. Calculated radiation doses ranged between 177 and 633 Gy for autonomous nodules and between 47 and 126 Gy for normal tissue. In thyroid cancer patients, doses between 350 and 1,420 Gy were achieved in thyroid remnants and between 70 and 170 Gy in tumour metastases. It is concluded that 124I and PET are suitable for evaluation of the dosimetry of radioiodine therapy in benign and malignant thyroid diseases. The applied technique might be particularly useful for quantitative dose-response studies in radioiodine treatment and further investigations of stunning phenomena.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029549     DOI: 10.1007/s00259-002-0775-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  A new PET probe, (18)F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine.

Authors:  Hyewon Youn; Jae Min Jeong; June-Key Chung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-07       Impact factor: 9.236

2.  (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution.

Authors:  Andreas Bockisch; Lutz Freudenberg; Sandra Rosenbaum; Walter Jentzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

3.  Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report.

Authors:  J S Lewis; M J Welch; L Tang
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

4.  Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system.

Authors:  Rebecca A Gregory; Claire A Hooker; Mike Partridge; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-14       Impact factor: 9.236

Review 5.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

6.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

7.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 8.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

Review 9.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

10.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.